2021ASH 静脉血栓栓塞症管理指南:癌症患者的预防和治疗

2021-02-23 美国血液病学会 Blood Adv . 2021 Feb 23;5(4):927-974

在癌症患者中,静脉血栓栓塞(VTE)是常见的并发症。静脉血栓栓塞症(VTE)是癌症患者中常见的并发症。癌症和VTE患者的发病和死亡风险明显增加。美国血液学学会(ASH)的这些循证指南旨在支持患者、临床

中文标题:

2021ASH 静脉血栓栓塞症管理指南:癌症患者的预防和治疗

英文标题:

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

发布机构:

美国血液病学会

发布日期:

2021-02-23

简要介绍:

在癌症患者中,静脉血栓栓塞(VTE)是常见的并发症。静脉血栓栓塞症(VTE)是癌症患者中常见的并发症。癌症和VTE患者的发病和死亡风险明显增加。美国血液学学会(ASH)的这些循证指南旨在支持患者、临床医生和其他卫生保健专业人员做出预防和治疗癌症患者静脉血栓栓塞症的决定。

相关资料下载:
[AttachmentFileName(sort=1, fileName=美国血液学会2021年静脉血栓栓塞治疗指南:癌症患者的预防和治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=1a1741c0020e111b, title=2021ASH 静脉血栓栓塞症管理指南:癌症患者的预防和治疗, enTitle=American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer, guiderFrom=Blood Adv . 2021 Feb 23;5(4):927-974, authorId=0, author=, summary=在癌症患者中,静脉血栓栓塞(VTE)是常见的并发症。静脉血栓栓塞症(VTE)是癌症患者中常见的并发症。癌症和VTE患者的发病和死亡风险明显增加。美国血液学学会(ASH)的这些循证指南旨在支持患者、临床, cover=https://img.medsci.cn/2021315/1615737691385_2020535.jpg, journalId=0, articlesId=null, associationId=25, associationName=美国血液病学会, associationIntro=美国血液病学会---是全球最大的关于血液疾病病因及治疗的专业协会。其使命为通过促进血液学的研究、临床护理、教育、培训及宣传而进一步促进对血液、骨髓、免疫、凝血及脉管系统疾病的了解、诊断与防治。ASH的官方杂志为《血液》,是该领域被引用最多的同行评议杂志,周刊。, copyright=0, guiderPublishedTime=Tue Feb 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>在癌症患者中,静脉血栓栓塞(VTE)是常见的并发症。静脉血栓栓塞症(VTE)是癌症患者中常见的并发症。癌症和VTE患者的发病和死亡风险明显增加。美国血液学学会(ASH)的这些循证指南旨在支持患者、临床医生和其他卫生保健专业人员做出预防和治疗癌症患者静脉血栓栓塞症的决定。</p>, tagList=[TagDto(tagId=57456, tagName=静脉血栓栓塞症)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=57456, guiderKeyword=静脉血栓栓塞症, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=17970, appHits=497, showAppHits=0, pcHits=1453, showPcHits=17473, likes=7, shares=47, comments=39, approvalStatus=1, publishedTime=Mon Mar 15 00:36:48 CST 2021, publishedTimeString=2021-02-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 15 00:01:38 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 13:42:31 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=美国血液学会2021年静脉血栓栓塞治疗指南:癌症患者的预防和治疗.pdf)])
美国血液学会2021年静脉血栓栓塞治疗指南:癌症患者的预防和治疗.pdf
下载请点击:
评论区 (29)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2022-04-26 su_yi_fei

    ***

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-13 1235354bm69暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-13 1235354bm69暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-13 1235354bm69暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-09 一己怀

    学习了

    0

拓展阅读

静脉血栓栓塞症抗凝治疗微循环血栓防治专家共识

中国微循环学会(CMS,Chinese Society of Microcirculation) 周围血管疾病专业委员会 静脉血栓栓塞症抗凝治疗微循环血栓防治共识专家组 · 2017-04-28

梯度压力袜用于静脉血栓栓塞症防治专家共识

国际血管联盟(IUA,International Union of Angiology) · 2019-09-30

2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南

首都医科大学附属北京天坛医院药学部 · 2021-11-21

中国减重与代谢外科围手术期静脉血栓栓塞症预防指南(2021版)

国家卫生健康委员会能力建设和继续教育外科学专家委员会减重与代谢外科专业委员会 · 2022-01-01

普通外科患者静脉血栓栓塞症风险评估与预防护理专家共识

中华护理学会外科护理专业委员会 · 2022-02-20